The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Shortening the timeline to first in human (FIH) clinical dosage form for oral / injectable delivery
Webinar On Demand
Lengthy early development timelines are common across new & emerging biotech companies for a multitude of reasons. Striking the right balance of speed, quality, risk, and investment allows you to shorten timelines and work with efficiency. Strategies adopted for a rapid development of a simple yet flexible format proves beneficial.
In recent years, with more clinical candidates being explored for niche indications, orphan drugs, and for indications with a rapid clinical end point, the pathway to the later clinical phase is short and there is not enough time to perform bridging studies. Hence a more scalable dosage form may need to be developed. Join our discussion highlighting the strategies that will bring success in early development for oral solid dosage form and for injectable formats.
Listen to this webinar to hear industry experts, Christy Eatmon and Kevin Kane, discuss:
- Striking the right balance of speed, quality, risk, and investment allows you to shorten timelines and work with efficiency
- Developing strategies for a rapid development of a simple yet flexible format for oral solid dosage & injectables
- Paving the pathway to later clinical phase and commercialization